Phase 3 Liver Cancer Trial, Terminated

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with a type of colorectal cancer called adenocarcinoma (a cancer that started in the colon or rectum).
• Your cancer had spread (Stage IV), but only to the liver — not to other parts of the body.
• You have had surgery with the goal of fully removing both your colorectal cancer and your liver tumors, with no cancer left at the edges of what was removed.
• You have received chemotherapy for a required minimum period (at least 3 months, but no more than 9 months total), including specific drug combinations — the exact requirements depend on your situation, so confirm the details with the trial site.
• Your cancer type has been confirmed by laboratory testing to be adenocarcinoma (including subtypes like mucinous adenocarcinoma).
• Your bone marrow, liver, and kidneys are working well enough, as shown by blood test results taken within 7 days before starting the study drug (confirm specific values with the trial site).
• You have had a CT or MRI scan of your chest, abdomen, and pelvis within 4 weeks before joining the trial.
• You are generally well enough to carry out daily activities with little or no limitation (this is measured using a standard scale called ECOG — a score of 0 or 1 is required).
• If you are a woman who could become pregnant, or a man, you agree to use effective contraception from the time you sign the consent form until 8 weeks after your last dose of the study drug.

Who may not be able to join:

• You are currently taking certain strong medications that affect how the body processes drugs — including some antifungals, antivirals, antibiotics, anti-seizure medicines, or St. John's Wort (confirm the full list with the trial site).
• You have used certain immune-boosting injections (such as white blood cell growth factors) within 3 weeks before signing the consent form.
• You have previously been treated with regorafenib or similar drugs that target a protein called VEGFR.
• You received more than 6 months of anti-cancer treatment after your liver surgery.
• You received certain targeted biological therapies (such as drugs targeting VEGFR or EGFR) after your liver surgery, unless those treatments began before surgery and continued only to finish a pre-planned number of doses.
• Your last chemotherapy dose or last cancer surgery happened more than 10 weeks before joining the trial (whichever happened later).
• Your cancer has spread to parts of the body other than the liver.
• You have received any systemic anti-cancer treatment within 4 weeks before starting the study drug.
• You are currently pregnant or breastfeeding.
• You have had a different type of cancer in the last 5 years, with some exceptions such as certain early-stage or non-invasive cancers that were fully treated (confirm with trial site).
• You have moderate to severe heart failure, recent unstable chest pain, or a heart attack within the last 6 months.
• You have a heart rhythm problem that requires medication to control (except for beta blockers or digoxin).
• You have high blood pressure that is not well controlled, even with medication.
• You have a rare adrenal gland tumor called pheochromocytoma.
• You have had a stroke, blood clot in a vein, or a blood clot in the lungs within the last 6 months.
• You have a known HIV infection.
• You have active or ongoing hepatitis B or C that requires antiviral treatment.
• You have a seizure condition that requires medication.
• You have any history of abnormal bleeding or a bleeding disorder, even if mild.
• You have had a serious bleeding event within 4 weeks before starting the study drug.
• You have any other serious illness or condition that could affect your safety or ability to participate in the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.